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Aim: The aim of the study is to investigate the impact of the cytochrome P450 2E1, which is the most efficient CYP450 family 
member in generating reactive oxygen species (ROS), on cellular energy metabolism of breast cancer cells and therefore the 
effects of CYP2E1 on breast carcinogenesis. Methods: The estrogen receptor positive MCF-7 and the triple negative MDA-
MB-231 breast cancer cells were used as experimental system to estimate ROS generation in these cells overexpressing CYP2E1 
and treated with the glycolytic inhibitors 3-bromopyruvate or 2-deoxyglucose in the presence or absence of the CYP2E1 inhibitor 
chlormethiazole. Adenosine triphosphate (ATP) assay was used to measure ATP production and lactate assay to quantify the efflux 
of lactic acid in breast cancer cells treated with the CYP2E1 inhibitor chlormethiazole, the mitochondrial membrane potential 
and cell viability assays were employed to assess the pathway of cellular energy production and cellular death respectively after 
treatment of MCF-7 and MDA-MB-231 with the CYP2E1 activator acetaminophen or the CYP2E1 inhibitor chlormethiazole. 
Results: The results indicated increased ROS generation in breast cancer cells overexpressing CYP2E1. ROS generation was 
differentially regulated in breast cancer cells upon treatment with the CYP2E1 inhibitor chlormethiazole. Chlormethiazole 
treated MCF-7 cells exhibited reduced lactate efflux implying that CYP2E1 directly or indirectly regulates the glycolytic rate 
in these cells. Furthermore the mitochondrial membrane potential of both MCF-7 and MDA-MB-231 cells was differentially 
affected by the CYP2E1 activator acetaminophen versus the CYP2E1 inhibitor chlormethiazole providing additional support for 
the involvement of CYP2E1 in energy metabolic pathways in breast cancer. Conclusion: Results presented in this study provide 
evidence to suggest that CYP2E1 regulates cellular energy metabolism of breast cancer cells in a manner dependent on cell type 
and potentially on the clinical staging of the disease therefore CYP2E1 is a possible breast cancer biomarker.
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INTRODUCTION
Reactive oxygen species (ROS) such as superoxide, hydroxyl 
radical, and hydrogen peroxide are metabolic by-products 
leaking from the complexes I and III of the mitochondrial 
respiratory chain.[1] Generation of high ROS levels is 
detrimental for the cells as it can lead to DNA damage and 
oxidation of proteins and lipids changing their functions.[2] 
Accumulating evidence indicates that apart from their 
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harmful effects ROS act as second messenger signalling 
molecules regulating numerous pathways including cell 
cycle,[3] autophagy,[4,5] apoptosis,[6] endoplasmic reticulum 
(ER) stress[7] and cellular energy metabolism.[8,9]
Sources of intracellular ROS generation include both 
organelles such as mitochondria, ER and peroxisomes as 
well as enzymes such as the NADPH oxidases, xanthine 
oxidase, lipoxygenases and cytochrome P450 enzymes, 
which produce ROS through their enzymatic activities.[10] 
CYP450 enzymes are mainly involved in the phase I 
metabolism of a wide range of exogenous and endogenous 
compounds oxidizing them to form more hydrophilic 
molecules thereby facilitating easier clearance.[11] In the 
case the monooxygenation reaction catalysed by CYP 
enzymes is uncoupled from the NADPH reaction instead 
of a monooxygenated substrate production of ROS 
occurs.[12] The CYP450 family member CYP2E1 is the 
most active enzyme of the family in terms of generating 
ROS sometimes inducing production of oxygen radicals 
even in the absence of substrates.[13]
Apart from the liver CYP2E1 gene expression has been 
detected in other tissues such as breast, lung, kidney 
and hematopoietic tissues[13] and has been reported to 
be over expressed in malignant compared to normal 
tissues.[14-17] CYP2E1 overexpression in cancer is 
attributed to the inflammatory conditions present in the 
tumor microenvironment characterised by increased 
inflammatory cytokine production which affects CYP2E1 
gene expression.[18-20] Several CYP2E1 dependent 
mechanisms contributing to tumorigenesis have been 
suggested including formation of toxic intermediate 
derivatives and activated carcinogens.[21-23] CYP2E1 
mediated ROS generation could also contribute to tumor 
development through pathways in which ROS play 
vital role such as DNA damage, enhanced angiogenic 
responses[24] autophagy[4,25,26] ER stress[27] and unfolded 
protein response (UPR).[28] Furthermore, research in our 
laboratory has indicated that CYP2E1 is differentially 
expressed in a manner dependent on the genetic background 
and the stage of breast cancer, regulating oxidative stress 
response and metastasis.[29]
Cancer cells produce energy predominantly through 
aerobic glycolysis -- a phenomenon also called Warburg 
effect -- rather than oxidative phosphorylation even in the 
presence of oxygen and functional mitochondria.[30] The 
Warburg effect is induced in cancer cells by increased 
cellular glucose uptake stimulated by ROS mediated 
upregulation of gene expression of glucose transporters 
such as GLUT-1.[31] On the other hand, experimental 
evidence supports the view that increased glycolytic 
conversion to pyruvate leads to ROS generation[32] 
suggesting the existence of an interrelation between ROS 
generation with glycolysis and vice versa.[9,33]
Taken together, the above mentioned observations allow 
the hypothesis that overexpression of CYP2E1 and the 
resultant elevated ROS production might regulate cellular 
energy metabolism in cancer cells pointing out CYP2E1 
as a potential cancer biomarker. The understanding of the 
interplay between CYP2E1 -- ROS generation -- cellular 
energy metabolism can provide important conclusions 
towards establishing novel breast cancer biomarkers 
and overcoming drug resistance. The estrogen receptor-
positive MCF-7 and the triple negative MDA-MB-231 
[estrogen receptor-negative, progesterone receptor-
negative and human epidermal growth factor receptor 2 
(HER2)-negative] breast cancer cells were used in this 
study to evaluate the impact of the CYP2E1 mediated ROS 
generation on the energy metabolism of these cells.
METHODS
Cell culture
The human breast carcinoma cell lines MCF-7 and MDA-
MB-231 [obtained from the European Collection of Cell 
Cultures (ECACC)] were maintained in Dulbecco’s 
modified Eagle’s medium (Sigma-Aldrich, Gillingham, 
UK), supplemented with 10% foetal bovine serum (Gibco, 
Paisley, UK) and 1% penicillin/streptomycin (Lonza, 
Allendale, NJ, USA) at 37°C in a humidified atmosphere 
containing 5% CO2. Cells were treated with 100 µM 
3-bromopyruvate (3BP) (Sigma-Aldrich) for 3 h, 20 
mmol/L 2-deoxyglucose (2DG) (Sigma-Aldrich)  for 24 h, 
2.5 mmol/L acetaminophen (APAP) (Sigma-Aldrich) for 
3 h and 20 μM chlormethiazole (CMZ) (Sigma-Aldrich) 
for 16 h.
Transient transfection
Transient transfections were carried out using the polyfect 
transfection reagent (Qiagen, Crawley, UK), according to 
the manufacturer’s instructions. Constructs used for ectopic 
expression included the pcDNA™3.1 (Invitrogen) and the 
pCI-neo-CYP2E1 (kindly provided by Dr. Cederbaum, 
Mount Sinai School of Medicine, New York).[29]
Measurement of ROS
Cells were grown until they reached 80% confluence 
prior to transient transfection and different treatments. 
ROS levels were measured using flow cytometry as 
described previously.[29] Cells were transiently transfected 
with the indicated constructs and 16 h after transfection 
they were harvested and incubated with 1 mL of APC-
H7-conjugated CD20 antibody (BD Biosciences, Franklin 
Lakes, NJ, USA) to detect only the cells ectopically 
expressing CYP2E1. Cells were then incubated with 
H2DCFDA (Invitrogen, Carlsbad CA, USA) in the dark 
at 37°C for 30 min and subjected to flow cytometry using 
CYAN-ADP flow cytometer (Dako, Glostrup, Denmark) 
following the fluorescence profile of the H2DCFDA and 
APC-H7 probes.
Adenosine triphosphate (ATP) assay
ATP levels were measured using the ViaLight plus kit 
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(Lonza, Slough, UK), based on the bioluminescent 
measurement of ATP present in cells. ATP monitoring 
reagent (AMR plus) was prepared by adding assay buffer 
into the vial containing the lyophilized AMR and incubated 
at room temperature for 15 min for complete rehydration. 
Cells were lysed in 50 μL of cell lysis reagent for 10 min. 
A total volume of 100 μL of cell lysate was added to a 
luminometer plate and 100 μL of AMR plus was added to 
the appropriate well. The plate was then incubated at room 
temperature for 2 min and values were obtained from the 
luminometer.
Lactate assay
To measure the lactate efflux MCF-7 and MDA-MB-231 
breast cancer cells were grown in 6 well plates and left 
untreated or treated with CYP2E1 specific inhibitor CMZ. 
Media was collected in a 96 well plate after treatment. Two 
microlitre of this media was mixed with 60 µL of lactate 
reagent and incubated at room temperature for 15 min 
and the absorbance was recorded at 540 nm. Lactic acid 
standard solutions (Trinity Biotech, Ireland) were used to 
plot the standard curve and the concentration of lactic acid 
present in the media was calculated accordingly. Lactate 
production rates were expressed as mmol/L.
Mitochondrial membrane potential
Mitochondrial transmembrane potential (Δψm) 
was measured using the cationic dye JC- 1 (5, 5, 6, 
6-tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine 
iodide) (ChemoMetec, Allerod, Denmark) using the 
NucleoCounter® NC-3000™ system. Cells were grown in 
6-well plates and treated with the CYP2E1 activator APAP 
Figure 1: ROS generation in MCF-7 and MDA-MB-231 cells ectopically expressing CYP2E1. MCF-7 and MDA-MB-231 cells were transiently transfected 
with a CYP2E1 expressing or the empty vector PCDNA3. ROS levels were determined using H2DCFDA fluorescent dye and flow cytometry only in the cells 
ectopically expressing CYP2E1 (co-transfected with CD20). FACS data were analyzed using Beckman Coulter Summit 4.1 software. (A) Histograms displaying 
ROS levels after transient transfection of CYP2E1 or pcDNA3 as indicated. Green coloured histograms represent ROS levels in cells transfected with CYP2E1 
and black histograms represent ROS levels in cells transfected with PCDNA3; (B) bar graphs representing ROS levels generated in cells transfected with 
PCDNA3 and CYP2E1 as indicated. Data are average of three independent experiments. ROS: reactive oxygen species; CYP: cytochrome P450
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Figure 2: CYP2E1 mediated ROS generation in breast cancer cells under diverse stress conditions. Graph indicating ROS levels generated in 3BP, 2DG 
and CMZ treated MCF-7 (A) and MDA-MB-231 (B) cells. Error bars represent mean ± SEM from three independent experiments. Statistical analysis was 
performed by one-way ANOVA followed by Tukey post hoc for multiple pair-wise comparisons. One asterisk indicates P < 0.05 and two asterisks P < 0.005. 
ROS: reactive oxygen species; CMZ: chlormethiazole
Figure 3: ATP production and lactate efflux in MCF-7 and MDA-MB-231 cells treated with the CYP2E1 inhibitor CMZ. MCF-7 and MDA-MB-231 cells were 
either left untreated or treated with the CYP2E1 specific inhibitor CMZ. ATP production (A and B) was determined using the ViaLight™ plus kit (Lonza, 
Slough, UK) and lactate efflux (C and D) using the lactate reagent (Trinity Biotech, Dublin, Ireland). Data are average of three independent experiments ± 
SEM; **P < 0.005. ATP: adenosine triphosphate; CMZ: chlormethiazole
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or the CYP2E1 inhibitor CMZ. After treatment, cells 
were stained with JC-1 and DAPI (ChemoMetec, Allerod, 
Denmark). Cellular JC-1 monomers and aggregates are 
detected as green and red fluorescence, respectively. 
Mitochondrial depolarization and apoptosis are revealed 
as a decrease in the red/green fluorescence intensity 
ratio. Necrotic and late apoptotic cells are detected as 
blue fluorescent (DAPI) cells. After staining cells were 
loaded on an 8-chamber NC-Slide A8™ and samples were 
analysed using the NC-3000™ system and the amount of 
blue, green and red fluorescence of the individual cells was 
quantified.
Cell viability assay
Cell viability was measured using the NucleoCounter® 
NC-3000™ system. Cell viability assay was used to detect 
changes in the intracellular level of (reduced) thiols. 
Cells were seeded in 6 well plates and cultured until they 
reached 80% confluence prior to different treatments. After 
the treatments, cell culture medium was aspirated and 
500 μL of cell dissociation buffer was added to cells for 
dissociation from culture plates. Five hundred microlitre 
of complete culture medium was added to quench the 
toxicity of dissociation buffer after cell dissociation. 
Then cells were stained with solution 5 as described by 
the manufacturer. Solution 5 (ChemoMetec, Allerod, 
Denmark) contains three different stains, each one of 
them staining either all nucleated cells (DAPI), dead cells 
(Propidium iodide) or viable cells (VB-48) (ChemoMetec, 
Allerod, Denmark) and the intensity of the stain depends 
on the GSH level. After staining, cells were loaded into an 
8-chanmber NC-slide. Samples were analysed using the 
NC-3000™ system.
RESULTS
The role of CYP2E1 in ROS generation in breast cancer 
cells has been investigated by our and other groups 
indicating that overexpression of this cytochrome P450 
family member in breast cancer cells coincides with 
elevated ROS levels implying that CYP2E1 is one of the 
intracellular sources of ROS.[29,34] To confirm that this 
is the case in the triple positive MCF-7 and the triple 
negative MDA-MB-231 cells CYP2E1 expressing vectors 
were transiently transfected and the ROS levels in mock 
and ectopically expressing CYP2E1 cells were followed as 
described in Materials and Methods. Increased ROS levels 
were recorded in both cell lines ectopically expressing 
Figure 4: Mitochondrial membrane potential (Δѱ) in breast cancer cells treated with the CYP2E1 activator APAP or the CYP2E1 inhibitor CMZ. Breast 
cancer cells were left untreated or treated with either the CYP2E1 inducer (APAP) or the CYP2E1 inhibitor (CMZ). Mitochondrial membrane potential 
(Δѱ) was determined using JC-1 and DAPI fluorescent dye (ChemoMetec, Allerod, Denmark) and the NucleoCounter NC3000. Data were analyzed using 
NucleoView software. (A) Histograms representing the mitochondrial membrane potential (Δѱ) in breast cancer cells under different stress conditions; (B) 
bar graphs representing the effect of APAP and CMZ treatments on mitochondrial membrane potential (Δѱ) in breast cancer cells. Error bars represent 
mean ± SEM from three independent experiments. Two asterisks indicate P < 0.005. APAP: acetaminophen; CMZ: chlormethiazole
            Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ July 29, 2016 ¦ 273
CYP2E1 compared to mock transfected cells [Figure 1B, 
compare bars 2 to bars 1 respectively].
To explore further the effects of CYP2E1 on the glycolytic 
pathway of energy production the glycolytic inhibitors 3BP 
and 2DG were used to inhibit glycolysis in MCF-7 and 
MDA-MB-231 cells either individually or in combination 
with the CYP2E1 inhibitor CMZ and the ROS generated 
under these conditions were monitored as described in 
Materials and Methods. Treatment of MCF-7 cells with 
3BP generated higher ROS levels compared to MCF-7 
cells treated with 2DG [Figure 2A, compare bar 1 to bar 3]. 
Combination of 3BP or 2DG treatment with CMZ resulted 
in dramatic decrease of ROS levels in MCF-7 cells [Figure 
2A, compare bar 2 to bar 1 and bar 4 to bar 3]. In contrast, 
in MDA-MB-231 cells CMZ had marginal effect on that 
observed when cells were treated with the glycolytic 
inhibitors 3BP and 2DG alone [Figure 2B, compare bars 
2 and 4 to bars 1 and 3 respectively] providing additional 
evidence that CYP2E1 exerts cell type dependent effects 
in ROS generation in a manner dependent on the genetic 
background and potentially their invasive potential.
Accumulating evidence supports the notion that 
ROS generation is associated with cellular energy 
production.[31,32,35] Results shown in Figure 1 indicate 
that CYP2E1 overexpression led to elevation of ROS in 
MCF-7 and MDA-MB-231 breast cancer cells implying a 
potential role of CYP2E1 in cellular energy metabolism. To 
test this hypothesis MCF-7 and MDA-MB-231 cells were 
treated with the CYP2E1 inhibitor CMZ and the levels of 
ATP produced under these conditions were determined as 
described in Methods. CMZ treatment of both MCF-7 and 
MDA-MB-231 cells did not have any significant effect on 
the ATP produced under these conditions [Figure 3A and 
3B]. To test whether the ROS levels’ profile observed in 
breast cancer cells was related to lactate production, MCF-
7 and MDA-MB-231 cells were treated with the CYP2E1 
Figure 5: Cell viability of breast cancer cells treated with the CYP2E1 activator APAP or the CYP2E1 inhibitor CMZ. Breast cancer cells were left untreated 
or treated with either the CYP2E1 activator APAP or the CYP2E1 inhibitor CMZ as indicated. Cell viability was calculated using the Vitality kit Assay 
(ChemoMetec, Allerod, Denmark). (A) Histogram representing cell viability under different stress conditions. Dead cells stained with PI are shown in the 
Q1ur gates; (B) bar graph representing the PI positive breast cancer cells treated with either APAP or CMZ. Error bars represent mean ± SEM from three 
independent experiments. Two asterisks indicate P < 0.005. APAP: acetaminophen; CMZ: chlormethiazole
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inhibitor CMZ[36,37] and lactate production was monitored 
as described in Methods. Results shown in Figure 3C 
indicate that inhibition of CYP2E1 in MCF-7 cells resulted 
in reduction of lactate production in these cells whereas 
inhibition of CYP2E1 in MDA-MB-231 cells did not have 
any effect on lactate production [Figure 3D] reiterating the 
concept that CYP2E1 effects are cell type dependent.
It is known that oxidative stress can trigger the 
mitochondrial permeability transition and Δψ collapse 
leading to defects in ATP production.[38] Taking into 
account these observations, we next assessed potential 
changes in the mitochondrial membrane potential in breast 
cancer cells treated with the CYP2E1 activator APAP 
or the CYP2E1 inhibitor CMZ. APAP treatment of both 
MCF-7 and MDA-MB-231 cells led to decrease of Δψ 
compared to untreated cells [Figure 4B, compare APAP 
white (0.652) and black (0.698) bars to UN white (1) 
and black (1) bars]. In contrast, CMZ treatment did not 
exert any effects on Δψ which remained the same as that 
observed in the untreated cells [Figure 4B, compare CMZ 
white and black bars to UN white and black bars]. These 
results indicate a potential role of CYP2E1 mediated ROS 
generation in the process of alterations of mitochondrial 
membrane potential.
Alterations in Δψ might in some cases lead to cell death[39] 
and in order to explore whether that was the case in breast 
cancer cells treated with APAP or CMZ MCF-7 and 
MDA-MB-231 cell death was determined by PI staining 
upon treatment with APAP or CMZ. APAP treatment of 
MCF-7 and MDA-MB-231 cells led to increased cell 
death in both cell lines (MCF-7 cells from 9% to 18% 
and MDA-MB-231 cells from 16% to 20%) [Figure 5B, 
compare APAP white and black bars to UN white and 
black bars]. CMZ treatment of both MCF-7 and MDA-
MB-231 cells did not exert any effects on cell death as 
it did not affect the percentage of PI positive compared 
to untreated MCF-7 and MDA-MB-231 cells [Figure 5B, 
compare CMZ white and black bars to UN white and black 
bars]. Taken together these results indicate that at least in 
part CYP2E1 mediated generation of ROS alters collapse 
of mitochondrial membrane potential determining cell 
survival or death in a cell type dependent manner.
DISCUSSION
Accumulating evidence supports the view that ROS 
generated by CYP2E1 activity mediate cell signalling 
events that promote alterations in the cellular physiology 
and disease development.[40-43] Studies in our and other 
laboratories have indicated diverse levels of CYP2E1 
gene expression in a manner dependent on the genetic 
background and the migratory potential of these 
cells.[16,17,29,34] CYP2E1 overexpression in breast cancer 
cells is involved in the alteration of numerous pathways 
linked to the disease such as cell cycle control, apoptosis, 
autophagy, ER stress and UPR.[29,44,45] In addition to these, 
another pathway that is regulated by the cellular redox 
state is cellular energy metabolism. The interrelation 
between ROS and aerobic glycolysis which is the main 
pathway through which cancer cells produce energy has 
been extensively investigated.[31,32] Since cytochrome P450 
enzymes are one of the endogenous sources of ROS[46,47] it 
was hypothesized that CYP450s might be involved in the 
regulation of cellular energy metabolism.
The role of the CYP2E1 mediated ROS generation in the 
energy metabolism of breast cancer cells was investigated 
in the estrogen receptor positive MCF-7 and estrogen 
receptor negative MDA-MB-231 cells.[48] Given that 
CYP2E1 gene expression is under the transcriptional 
control of factors responsive to inflammation[19,29,49,50] it 
was theorized that inhibition of glycolysis in breast cancer 
cells bearing diverse genetic background would lead to 
alternative CYP2E1 cellular levels and hence dissimilar 
ROS.[42] On the other side inhibition of glycolysis would 
lead to increased ROS generation[31] that could be altered 
by CYP2E1 enzymatic activity.[42,51-53] In accord with 
published results treatment of both MCF-7 and MDA-
MB-231 cells with the glycolytic inhibitors 3BP and 
2DG increased ROS levels in the two cell lines.[33,54,55] 
Combination of either 3BP or 2DG with the CYP2E1 
inhibitor CMZ reduced dramatically the oxygen radicals’ 
levels in the MCF-7 but not in the MDA-MB-231 cells 
[Figure 2] implying that the dissimilar genetic background 
in the two cell lines (wild type ER and p53 in MCF-7 and 
defective ER and mutated p53 in MDA-MB-231 cells) 
determines the differential response of these cells to the 
glycolytic and CYP2E1 inhibitors.[56]
The observation that CMZ decreased ROS generation 
stimulated by 3BP and 2DG treatment in MCF-7 cells 
prompted our interest to explore the possibility that 
CYP2E1 is involved in the process of energy metabolism 
in breast cancer cells. The potential link between CYP2E1 
and energy metabolism was investigated in the MCF-7 
and MDA-MB-231 cells by estimating the ATP production 
after treating these cells with the CYP2E1 inhibitor CMZ. 
Results shown in Figure 3 indicate that CMZ treatment 
did not significantly affect ATP generation in the two cell 
lines implying that if CYP2E1 had inhibitory effect on 
one of the pathways of ATP generation another pathway 
compensates for the loss facilitating cells to meet their 
energy requirements,[57] or CYP2E1 is not involved in 
ATP production in these cells. To answer these questions 
the lactate concentration was determined in CMZ treated 
MCF-7 and MDA-MB-231 cells.[58] CMZ treatment 
reduced lactate efflux in MCF-7 but not in MDA-MB-231 
cells [Figure 3C and 3D] implying that CYP2E1 exerts 
cell type dependent effects on energy metabolism. These 
results are in line with those shown in Figure 2 indicating 
reversion of the effect of the glycolytic inhibitors 3BP 
and 2DG on ROS levels by CMZ in MCF-7 cells, and 
published studies reporting that high ROS levels induce 
hypoxia inducible factor 1 alpha (HIF-1α) thereby 
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inducing lactate dehydrogenase (LDH-A) gene expression 
and hence lactate efflux.[58]
Depolarization of the mitochondrial membrane is 
determined by the gradient of protons across the 
mitochondrial membrane. Opening of the mitochondrial 
permeability transition pore (PTP) permitting influx or 
efflux of protons can lead to mitochondrial membrane 
depolarization. Proteins involved in the regulation of 
the PTP opening are susceptible to redox modifications 
therefore high levels of ROS may lead to PTP opening and 
induce mitochondrial membrane depolarization.[59] Given 
that overexpression [Figure 1] or inhibition of CYP2E1 
altered the redox state of MCF-7 and MDA-MB-231 cells 
[Figure 2] we were interested to study potential changes of 
the mitochondrial membrane potential in breast cancer cells 
attributed to the activation or inhibition of the CYP2E1 
enzymatic activity. Reduced mitochondrial membrane 
potential was observed in both MCF-7 and MDA-MB-231 
cells treated with the CYP2E1 activator APAP whereas no 
changes in mitochondrial membrane depolarization were 
recorded in these cells treated with the CYP2E1 inhibitor 
CMZ [Figure 4].
Cell death through the intrinsic pathway of apoptosis 
is triggered by sustained mitochondrial membrane 
depolarization.[59] To investigate the potential role of 
CYP2E1 in inducing cell death by mediating alterations 
in the mitochondrial membrane depolarization MCF-7 and 
MDA-MB-231 cells were treated with either the CYP2E1 
activator APAP or the CYP2E1 inhibitor CMZ and cellular 
viability was assessed. APAP induced cell death in both 
MCF-7 and MDA-MB-231 cells while CMZ induced cell 
death only in MCF-7 cells [Figure 5] reiterating the view 
that CYP2E1 effects are cell type specific.
Taken together results presented in this study provide 
evidence to support the concept that CYP2E1 regulates 
cellular energy metabolism in a cell type dependent manner 
affecting predominately this pathway in less invasive and 
early stages of breast cancer represented by the MCF-7 
cells. Although these results require validation in an in 
vivo system they endorse the conclusion that CYP2E1 
cellular levels can be a prognostic indicator and a potential 
breast cancer biomarker.
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